NEW YORK (GenomeWeb News) – Epistem today announced a research collaboration with GlaxoSmithKline to use its amplification technology to gain a better understanding of fibrosis.
The Manchester, UK-based firm will use its RNA-Amp technology to identify characteristics of diseased fibrotic tissue, Epistem said. The deal is for three years, but further terms were not disclosed.
Epistem's RNA-Amp technology provides gene expression information from small tissue samples and low number of cells, such as those from cells at the base of a single hair follicle or laser captured microdissected samples, it said.
Last week, Epistem said it had reached a deal with Xcelris Labs of India for the sales and marketing of its rapid molecular tuberculosis diagnostic test.